TriangleNCT02426125 · OUTCOME
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- units on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)
What was measured
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. A unique EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Scores range from 0 (death) to 1 (perfect health), but scores \<0 are possible based on the algorithm.
Analysis population: All randomized participants with baseline and 30-day follow-up data.
Groups in this outcome
Ramucirumab + Docetaxel
Ramucirumab (10 mg/kg) IV plus docetaxel IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Placebo + Docetaxel
Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
| Group | Source count |
|---|---|
| Ramucirumab + Docetaxel | 83 |
| Placebo + Docetaxel | 102 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ramucirumab + Docetaxel | -0.10 | 0.26 | Not reported | Not reported | Not reported |
| Placebo + Docetaxel | -0.19 | 0.26 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.26
- value
- -0.10
- group Id
- OG001
- spread
- 0.26
- value
- -0.19
- denoms
- counts
- group Id
- OG000
- value
- 83
- group Id
- OG001
- value
- 102
- units
- Participants
- description
- The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. A unique EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Scores range from 0 (death) to 1 (perfect health), but scores \<0 are possible based on the algorithm.
- dispersion Type
- Standard Deviation
- groups
- description
- Ramucirumab (10 mg/kg) IV plus docetaxel IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
- id
- OG000
- title
- Ramucirumab + Docetaxel
- description
- Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
- id
- OG001
- title
- Placebo + Docetaxel
- param Type
- MEAN
- population Description
- All randomized participants with baseline and 30-day follow-up data.
- reporting Status
- POSTED
- time Frame
- Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)
- title
- Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
- type
- SECONDARY
- unit Of Measure
- units on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice